메뉴 건너뛰기




Volumn 15, Issue 2, 2009, Pages 147-150

Pharmacist intervention in treatment of patients with genotype 1 chronic hepatitis C

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

EID: 63349100039     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2009.15.2.147     Document Type: Article
Times cited : (24)

References (26)
  • 2
    • 0032538246 scopus 로고    scopus 로고
    • Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease
    • Center for Disease Control and Prevention CDC
    • Center for Disease Control and Prevention (CDC). Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recommen Rep. 1998;47(RR-19):1-39.
    • (1998) MMWR Recommen Rep , vol.47 , Issue.RR-19 , pp. 1-39
  • 3
    • 0033584440 scopus 로고    scopus 로고
    • The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
    • Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341(8):556-62.
    • (1999) N Engl J Med , vol.341 , Issue.8 , pp. 556-562
    • Alter, M.J.1    Kruszon-Moran, D.2    Nainan, O.V.3
  • 4
    • 0036829649 scopus 로고    scopus 로고
    • National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 - June 10-12, 2002. Hepatology. 2002;36(5 Suppl 1):S3-S20.
    • National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 - June 10-12, 2002. Hepatology. 2002;36(5 Suppl 1):S3-S20.
  • 5
    • 1642320241 scopus 로고    scopus 로고
    • Understanding hepatitis C
    • McHutchison JG. Understanding hepatitis C. Am J Manag Care. 2004;10(2 Suppl):S21-S29.
    • (2004) Am J Manag Care , vol.10 , Issue.2 SUPPL.
    • McHutchison, J.G.1
  • 6
    • 27644542713 scopus 로고    scopus 로고
    • Chronic hepatitis C: An age Wave of disease burden
    • McHutchison JG, Bacon BR. Chronic hepatitis C: an age Wave of disease burden. Am J Manag Care. 2005;11(10 Suppl):S286-S295.
    • (2005) Am J Manag Care , vol.11 , Issue.10 SUPPL.
    • McHutchison, J.G.1    Bacon, B.R.2
  • 7
    • 0030031879 scopus 로고    scopus 로고
    • Hepatitis C virus genotypes in different risk populations in Spain. The Hepatitis-HIV Spanish Study Group
    • Bravo R, Soriano V, Garcia-Samaniego J, et al. Hepatitis C virus genotypes in different risk populations in Spain. The Hepatitis-HIV Spanish Study Group. J Infect Dis. 1996;173(2):509-10.
    • (1996) J Infect Dis , vol.173 , Issue.2 , pp. 509-510
    • Bravo, R.1    Soriano, V.2    Garcia-Samaniego, J.3
  • 8
    • 0032547938 scopus 로고    scopus 로고
    • Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
    • McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485-92.
    • (1998) N Engl J Med , vol.339 , pp. 1485-1492
    • McHutchison, J.G.1    Gordon, S.C.2    Schiff, E.R.3
  • 9
    • 0032585237 scopus 로고    scopus 로고
    • Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
    • Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352(9138):1426-32.
    • (1998) Lancet , vol.352 , Issue.9138 , pp. 1426-1432
    • Poynard, T.1    Marcellin, P.2    Lee, S.S.3
  • 10
    • 0034324083 scopus 로고    scopus 로고
    • Pegylated interferon alfa-2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data
    • Glue P, Fang JW, Rourizer-Panis R, et al. Pegylated interferon alfa-2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther. 2000;68(5):556-67.
    • (2000) Clin Pharmacol Ther , vol.68 , Issue.5 , pp. 556-567
    • Glue, P.1    Fang, J.W.2    Rourizer-Panis, R.3
  • 11
    • 32344431567 scopus 로고    scopus 로고
    • Chronic hepatitis C virus management: 2000-2005 update
    • Hughes CA, Shafran SD. Chronic hepatitis C virus management: 2000-2005 update. Ann Pharmacother. 2006;40(1):74-82.
    • (2006) Ann Pharmacother , vol.40 , Issue.1 , pp. 74-82
    • Hughes, C.A.1    Shafran, S.D.2
  • 12
    • 0035934568 scopus 로고    scopus 로고
    • Pegylated interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
    • Manns MP, McHutchison JG, Gordon SC, et al. Pegylated interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-65.
    • (2001) Lancet , vol.358 , Issue.9286 , pp. 958-965
    • Manns, M.P.1    McHutchison, J.G.2    Gordon, S.C.3
  • 13
    • 30044432484 scopus 로고    scopus 로고
    • American Gastroenterological Association technical review on the management of hepatitis C
    • Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006;130(1):231-64.
    • (2006) Gastroenterology , vol.130 , Issue.1 , pp. 231-264
    • Dienstag, J.L.1    McHutchison, J.G.2
  • 14
    • 27644514603 scopus 로고    scopus 로고
    • Treatment issues with chronic hepatitis C: Special populations and pharmacy strategies
    • Bacon BR, McHutchison JG. Treatment issues with chronic hepatitis C: special populations and pharmacy strategies. Am J Manag Care. 2005;11(10 Suppl):S296-S306.
    • (2005) Am J Manag Care , vol.11 , Issue.10 SUPPL.
    • Bacon, B.R.1    McHutchison, J.G.2
  • 15
    • 0036788338 scopus 로고    scopus 로고
    • Adherence tp combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C
    • McHutchison JG, Manns M, Patel K, et al. Adherence tp combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123(4):1061-69.
    • (2002) Gastroenterology , vol.123 , Issue.4 , pp. 1061-1069
    • McHutchison, J.G.1    Manns, M.2    Patel, K.3
  • 16
    • 33646434799 scopus 로고    scopus 로고
    • Clinical pharmacists and inpatient medical care: A systematic review
    • Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med. 2006;166(9):955-64.
    • (2006) Arch Intern Med , vol.166 , Issue.9 , pp. 955-964
    • Kaboli, P.J.1    Hoth, A.B.2    McClimon, B.J.3    Schnipper, J.L.4
  • 17
    • 39649123695 scopus 로고    scopus 로고
    • The impact of clinical pharmacists on drug-related problems and clinical outcomes
    • Viktil KK, Blix HS. The impact of clinical pharmacists on drug-related problems and clinical outcomes. Basic Clin Pharmacol Toxicoil. 2008;102(3):275-80.
    • (2008) Basic Clin Pharmacol Toxicoil , vol.102 , Issue.3 , pp. 275-280
    • Viktil, K.K.1    Blix, H.S.2
  • 18
    • 34447567398 scopus 로고    scopus 로고
    • Chronic hepatitis C virus infection: A review for pharmacists
    • Rodis J. Chronic hepatitis C virus infection: a review for pharmacists. J Am Pharm Assoc. 2007;47(4):508-20.
    • (2007) J Am Pharm Assoc , vol.47 , Issue.4 , pp. 508-520
    • Rodis, J.1
  • 19
    • 51849106467 scopus 로고    scopus 로고
    • Treatment options for patients with hepatitis C: Role of pharmacists in optimizing treatment response and managing adverse events
    • Smith JP. Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment response and managing adverse events. Pharmacotherapy. 2008;28(9):1151-61.
    • (2008) Pharmacotherapy , vol.28 , Issue.9 , pp. 1151-1161
    • Smith, J.P.1
  • 20
    • 1842632416 scopus 로고    scopus 로고
    • Population-based hepatitis C surveillance and treatment in a national managed care organization
    • Shatin D, Schech SD, Patel K, McHutchison JG. Population-based hepatitis C surveillance and treatment in a national managed care organization. Am J Manag Care. 2004;10(4):250-56.
    • (2004) Am J Manag Care , vol.10 , Issue.4 , pp. 250-256
    • Shatin, D.1    Schech, S.D.2    Patel, K.3    McHutchison, J.G.4
  • 21
    • 33947587903 scopus 로고    scopus 로고
    • Evaluation of a pharmacist-managed hepatitis C care clinic
    • Smith JP, Dong MH, Kaunitz JD. Evaluation of a pharmacist-managed hepatitis C care clinic. Am J Health-Syst Pharm. 2007; 64(6):632-36.
    • (2007) Am J Health-Syst Pharm , vol.64 , Issue.6 , pp. 632-636
    • Smith, J.P.1    Dong, M.H.2    Kaunitz, J.D.3
  • 22
    • 24144456553 scopus 로고    scopus 로고
    • Patient education and treatment strategies implemented at a pharmacist-managed hepatitis C virus clinic
    • Kolor B. Patient education and treatment strategies implemented at a pharmacist-managed hepatitis C virus clinic. Pharmacotherapy. 2005;25(9):1230-41.
    • (2005) Pharmacotherapy , vol.25 , Issue.9 , pp. 1230-1241
    • Kolor, B.1
  • 23
    • 37849042201 scopus 로고    scopus 로고
    • Into the light: Strategies for battling hepatitis C
    • Bacon BR, McHutchison JG. Into the light: strategies for battling hepatitis C. Am J Manag Care. 2007;13(Suppl 12):S319-S326.
    • (2007) Am J Manag Care , vol.13 , Issue.SUPPL. 12
    • Bacon, B.R.1    McHutchison, J.G.2
  • 24
    • 37849049890 scopus 로고    scopus 로고
    • Making it happen: Managed care considerations in vanquishing hepatitis C
    • McHutchison JG, Bacon BR, Owens GS. Making it happen: managed care considerations in vanquishing hepatitis C. Am J Manag Care. 2007;13(Suppl 12):S327-S336.
    • (2007) Am J Manag Care , vol.13 , Issue.SUPPL. 12
    • McHutchison, J.G.1    Bacon, B.R.2    Owens, G.S.3
  • 25
    • 58749112970 scopus 로고    scopus 로고
    • Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirin
    • Weiss JJ, Bhatti L, Dieterich DT, et al. Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirin. Aliment Pharmacol Ther. 2008;28(3):289-93.
    • (2008) Aliment Pharmacol Ther , vol.28 , Issue.3 , pp. 289-293
    • Weiss, J.J.1    Bhatti, L.2    Dieterich, D.T.3
  • 26
    • 34547222990 scopus 로고    scopus 로고
    • Virahep-C Study Group. Assessing the validity of self-reported medication adherence in hepatitis C treatment
    • Smith SC, Wahed AS, Kelley SS, Conjeevaram HS, Robuck PR, Fried MW; Virahep-C Study Group. Assessing the validity of self-reported medication adherence in hepatitis C treatment. Ann Pharmacother. 2007;41(7):1116-23.
    • (2007) Ann Pharmacother , vol.41 , Issue.7 , pp. 1116-1123
    • Smith, S.C.1    Wahed, A.S.2    Kelley, S.S.3    Conjeevaram, H.S.4    Robuck, P.R.5    Fried, M.W.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.